CN104364656A - 诊断和监视癌症的体外方法 - Google Patents

诊断和监视癌症的体外方法 Download PDF

Info

Publication number
CN104364656A
CN104364656A CN201380030845.9A CN201380030845A CN104364656A CN 104364656 A CN104364656 A CN 104364656A CN 201380030845 A CN201380030845 A CN 201380030845A CN 104364656 A CN104364656 A CN 104364656A
Authority
CN
China
Prior art keywords
cell
cells
tregs
tumor
vitro method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380030845.9A
Other languages
English (en)
Chinese (zh)
Inventor
J.巴滕科瓦
R.斯皮塞克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sotio AS
Original Assignee
Sotio AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sotio AS filed Critical Sotio AS
Publication of CN104364656A publication Critical patent/CN104364656A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4915—Blood using flow cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ecology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN201380030845.9A 2012-07-02 2013-06-27 诊断和监视癌症的体外方法 Pending CN104364656A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12174539.2 2012-07-02
EP20120174539 EP2682750A1 (en) 2012-07-02 2012-07-02 In vitro method for the diagnosis and surveillance of cancer
US201261672941P 2012-07-18 2012-07-18
US61/672,941 2012-07-18
PCT/EP2013/063448 WO2014005909A1 (en) 2012-07-02 2013-06-27 In vitro method for the diagnosis and surveillance of cancer

Publications (1)

Publication Number Publication Date
CN104364656A true CN104364656A (zh) 2015-02-18

Family

ID=46397089

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380030845.9A Pending CN104364656A (zh) 2012-07-02 2013-06-27 诊断和监视癌症的体外方法

Country Status (18)

Country Link
US (1) US20150337384A1 (enExample)
EP (2) EP2682750A1 (enExample)
JP (1) JP2015526709A (enExample)
KR (1) KR20150035521A (enExample)
CN (1) CN104364656A (enExample)
AU (1) AU2013286134A1 (enExample)
BR (1) BR112014026661A2 (enExample)
CA (1) CA2872668A1 (enExample)
CL (1) CL2014002975A1 (enExample)
EA (1) EA201500080A1 (enExample)
HK (1) HK1202618A1 (enExample)
IL (1) IL236197A0 (enExample)
IN (1) IN2015DN00678A (enExample)
MX (1) MX2014013079A (enExample)
PH (1) PH12014502436A1 (enExample)
SG (1) SG11201406581UA (enExample)
WO (1) WO2014005909A1 (enExample)
ZA (1) ZA201409298B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105247365A (zh) * 2013-05-30 2016-01-13 莫洛根股份公司 用于癌症治疗的预测性生物标记物
CN108135945A (zh) * 2015-06-22 2018-06-08 哈佛大学校长及研究员协会 固有层调节性t细胞的诱导
CN108508196A (zh) * 2018-04-13 2018-09-07 沈阳汇敏源生物科技有限责任公司 一种检测人调节性t细胞亚型的试剂盒及检测方法
CN111316101A (zh) * 2017-05-19 2020-06-19 皇家墨尔本理工大学 预测对环磷酰胺疗法的反应者

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6605506B2 (ja) 2014-02-24 2019-11-13 ヴェンタナ メディカル システムズ， インク． ＣＤ３、ＣＤ８、ＣＤ２０及びＦｏｘＰ３の同時検出によりがんに対する免疫応答をスコア化するための方法、キット、及びシステム
CA2942721A1 (en) * 2014-03-14 2015-09-17 Czerniecki, Brian J. Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US20160266125A1 (en) * 2015-03-12 2016-09-15 John Wayne Cancer Institute Methods of treating and predicting progression of cancer based on t cell subsets
JP6100867B1 (ja) * 2015-11-06 2017-03-22 振武 曽 免疫状態の分析のための検査方法
CN106932576A (zh) * 2017-03-22 2017-07-07 山东大学深圳研究院 一种人调节性t细胞的免疫抑制功能的检测方法
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
DK3820573T3 (da) 2018-07-10 2023-10-23 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP7259019B2 (ja) * 2018-09-20 2023-04-17 ヴェンタナ メディカル システムズ， インク． フローサイトメトリデータを分析するためのサイズに基づくゲーティング

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANNON MJ ET AL: "Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage?", 《EXPERT OPIN BIOL THER》 *
DH MUNN: "Th17 cells in ovarian cancer", 《BLOOD》 *
ILONA KRYCZEK ET AL: "Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments", 《BLOOD》 *
KRYCZEK I ET AL: "IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer", 《J IMMUNOL.》 *
L. J. CHI ET AL: "Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma", 《CLINICAL & EXPERIMENTAL IMMUNOLOGY》 *
TYLER J CURIEL ET AL: "Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival", 《NATURE MEDICINE》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105247365A (zh) * 2013-05-30 2016-01-13 莫洛根股份公司 用于癌症治疗的预测性生物标记物
CN108135945A (zh) * 2015-06-22 2018-06-08 哈佛大学校长及研究员协会 固有层调节性t细胞的诱导
CN111316101A (zh) * 2017-05-19 2020-06-19 皇家墨尔本理工大学 预测对环磷酰胺疗法的反应者
CN111316101B (zh) * 2017-05-19 2023-11-10 皇家墨尔本理工大学 预测对环磷酰胺疗法的反应者
CN108508196A (zh) * 2018-04-13 2018-09-07 沈阳汇敏源生物科技有限责任公司 一种检测人调节性t细胞亚型的试剂盒及检测方法
CN108508196B (zh) * 2018-04-13 2020-10-27 何韶衡 一种检测人调节性t细胞亚型的试剂盒及检测方法

Also Published As

Publication number Publication date
AU2013286134A1 (en) 2015-01-22
EP2682750A1 (en) 2014-01-08
PH12014502436A1 (en) 2015-01-12
IN2015DN00678A (enExample) 2015-06-26
KR20150035521A (ko) 2015-04-06
CA2872668A1 (en) 2014-01-09
EA201500080A1 (ru) 2015-06-30
SG11201406581UA (en) 2015-01-29
US20150337384A1 (en) 2015-11-26
ZA201409298B (en) 2015-12-23
WO2014005909A1 (en) 2014-01-09
MX2014013079A (es) 2014-12-08
HK1202618A1 (en) 2015-10-02
JP2015526709A (ja) 2015-09-10
BR112014026661A2 (pt) 2017-06-27
IL236197A0 (en) 2015-01-29
EP2867677A1 (en) 2015-05-06
CL2014002975A1 (es) 2015-04-24

Similar Documents

Publication Publication Date Title
CN104364656A (zh) 诊断和监视癌症的体外方法
Reiss et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Lin et al. Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients
Fialová et al. Dynamics of T‐cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T‐cells
Tang et al. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma
Liotta et al. Frequency of regulatory T cells in peripheral blood and in tumour‐infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma
Vujanovic et al. CD56dim CD16− natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-α
Ghirelli et al. Breast cancer Cell–derived GM-CSF licenses regulatory Th2 induction by plasmacytoid predendritic cells in aggressive disease subtypes
Talpur et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma
Zhang et al. The role of CCL20/CCR6 axis in recruiting Treg cells to tumor sites of NSCLC patients
Rusakiewicz et al. NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients
Pawelec et al. MDSCs, ageing and inflammageing
Morandi et al. Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins
Han et al. Hyperprogression: a novel response pattern under immunotherapy
Zhang et al. DUSP1 phosphatase regulates the proinflammatory milieu in head and neck squamous cell carcinoma
Masuhiro et al. Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer
Dwivedi et al. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study
JP2011526148A (ja) 遺伝子ｆｏｘＰ３のＴＳＤＲ領域のＤＮＡメチル化分析による制御性Ｔ細胞のＤＮＡメチル化分析
Bahria-Sediki et al. Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma
Wågsäter et al. Quantification of the chemokines CCL17 and CCL22 in human colorectal adenocarcinomas
Hori et al. Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model
Wang et al. Clinical implication of naive and memory T cells in locally advanced cervical cancer: A proxy for tumor biology and short-term response prediction.
Goodyear et al. Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments
Chang et al. Exploring the evolution of T cell function and diversity across different stages of non-small cell lung cancer
US20240066061A1 (en) A cxcr3+ cell or cell preparation for use in cancer treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202618

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150218

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1202618

Country of ref document: HK